Repligen resumed with an Overweight at Stephens

Stephens analyst Steven Etoch resumed coverage of Repligen (RGEN) with an Overweight rating and $160 price target The firm views Repligen as the leader within the bioprocessing industry. It faces industry tailwinds from the increase in the late stage pipeline of biologics and biosimilars entering the market continue which continue to drive an increasing need for bioprocessing capabilities, the analyst tells investors in a research note.